Drug approval : entrectinib and larotrectinib - cancers with NTRK fusion

被引：2
|
作者：
Delaye, Matthieu [1 ,2 ]
Rodrigues, Manuel [3 ,4 ]
机构：
[1] Hop Tenon, Serv Oncol Med & Therapie Cellulaire, 4 Rue Chine, F-75020 Paris, France
[2] Assoc Enseignement & Rech Internes Oncol AERIO, 149 Ave Maine, F-75014 Paris, France
[3] PSL Res Univ, Inst Curie, Dept Oncol Med, 26 Rue Ulm, F-75005 Paris, France
[4] PSL Res Univ, Inst Curie, INSERM, U830, 26 Rue Ulm, F-75005 Paris, France
来源：
BULLETIN DU CANCER | 2020年 / 107卷 / 11期
关键词：
POSITIVE SOLID TUMORS;
D O I：
10.1016/j.bulcan.2020.09.009
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1085 / +
页数：2
相关论文
共 50 条
  • [21] Entrectinib Amazing Efficacy in a Case of Lung Atypical Carcinoid with NTRK Gene Fusion
    Shi, H.
    Li, X.
    Bai, C.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S689 - S689
  • [22] Evaluating larotrectinib for the treatment of advanced solid tumors harboring an NTRK gene fusion
    Filippi, Roberto
    Depetris, Ilaria
    Satolli, Maria Antonietta
    EXPERT OPINION ON PHARMACOTHERAPY, 2021, 22 (06) : 677 - 684
  • [23] Updated efficacy and safety of entrectinib in patients (pts) with NTRK fusion-positive (NTRK-fp) NSCLC
    Cho, B. C.
    Chiu, C-H.
    Massarelli, E.
    Chawla, S. P.
    Buchschacher, G. L., Jr.
    Goto, K.
    Kim, S-W.
    Overbeck, T. R.
    Loong, H. H. F.
    Chee, C. E.
    Garrido, P.
    Heinzmann, S.
    Pitcher, B.
    John, T.
    ANNALS OF ONCOLOGY, 2022, 33 : S82 - S83
  • [24] Comment on: A newborn with a large NTRK fusion positive infantile fibrosarcoma successfully treated with larotrectinib
    Slomovic, Alana
    Amaral, Terry
    Lobko, Igor
    Siegel, David N.
    Goldfisher, Rachelle
    Kessel, Rachel
    Levy, Carolyn Fein
    PEDIATRIC BLOOD & CANCER, 2021, 68 (06)
  • [25] THE POTENTIAL LONG-TERM COMPARATIVE EFFECTIVENESS OF LAROTRECTINIB VS. ENTRECTINIB FOR TREATMENT OF METASTATIC FUSION-POSITIVE CANCERS IN CHILDREN AND YOUNG ADULTS
    Suh, K.
    Kang, A.
    Singh, R.
    Williamson, T.
    Sullivan, S.
    VALUE IN HEALTH, 2024, 27 (06) : S44 - S45
  • [26] Neurotrophic Tyrosine Receptor Kinase (NTRK) Gene Fusion Testing in Clinical Trials of Larotrectinib
    Rudzinski, E.
    Hong, D.
    Rudolph, M.
    Lockwood, C.
    Reeves, J.
    Moh, A.
    Nogai, H.
    Laetsch, T.
    Drilon, A.
    JOURNAL OF MOLECULAR DIAGNOSTICS, 2020, 22 (11): : S79 - S79
  • [27] Larotrectinib effective against TRK-fusion-positive cancers
    Peter Sidaway
    Nature Reviews Clinical Oncology, 2018, 15 : 264 - 264
  • [28] NTRK Fusion-Positive Congenital Spinal Glioblastoma treated with Carboplatin, Etoposide, and Larotrectinib
    Vallis, Graham
    PEDIATRICS, 2021, 147 (03)
  • [29] A case of complete response to entrectinib in NTRK fusion gene-positive parotid carcinoma
    Moriyama, Etsuko
    Nagasu, Sachiko
    Tanaka, Toshimitsu
    Shigyo, Hirona
    Shimotsuura, Yasutaka
    Takashi, Kurita
    Ono, Takeharu
    Umeno, Hirohito
    Akiba, Jun
    Naito, Yoshiki
    Miwa, Keisuke
    ANNALS OF ONCOLOGY, 2023, 34 : S1457 - S1458
  • [30] Entrectinib approval by EMA reinforces options for ROS1 and tumour agnostic NTRK targeted cancer therapies
    Ardini, Elena
    Siena, Salvatore
    ESMO OPEN, 2020, 5 (05)
12345